Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | February 26, 2026 | May 20, 2026 |
| Imunon, Inc.IMNN · Entity 8041 | Director · President and CEO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date February 26, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2036-02-26 | Direct | 150,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 150,000 · Balance 150,000 F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
F2: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Imunon, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 116,174 |
Reported balance
After 2026-10-09 transaction · row 1
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 2,977 · Balance 116,174 F1: Stock granted in lieu of cash for portion of base salary |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 778 |
Reported balance
Holding disclosure · report date 2026-10-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 778 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock granted in lieu of cash for portion of base salary
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 20:06 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 2,977 | $1.08 | $3,215.16 |
DisclosureSEC source: 0001437749-26-032562 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,174 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| September 25, 2026 Filed Sep 28, 2026 20:30 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 6,697 | $1.41 | $9,442.77 |
DisclosureSEC source: 0001437749-26-031362 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,197 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 16:42 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 5,504 | $1.47 | $8,090.88 |
DisclosureSEC source: 0001437749-26-030414 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,580 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| August 28, 2026 Filed Sep 1, 2026 20:09 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 6,822 | $1.60 | $10,915.20 |
DisclosureSEC source: 0001437749-26-029408 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,076 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| August 14, 2026 Filed Aug 17, 2026 20:22 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 6,615 | $1.65 | $10,914.75 |
DisclosureSEC source: 0001437749-26-028187 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,254 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:10 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 5,010 | $1.59 | $7,965.90 |
DisclosureSEC source: 0001437749-26-025655 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,639 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 20:14 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 4,907 | $1.83 | $8,979.81 |
DisclosureSEC source: 0001437749-26-023946 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,629 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 20:56 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 2,534 | $1.91 | $4,839.94 |
DisclosureSEC source: 0001437749-26-022941 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,722 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 20:21 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 67,150 | $1.72 | $115,498.00 |
DisclosureSEC source: 0001437749-26-022001 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,188 F1 · shares: Stock granted in lieu of cash for 50% of 2025 annual cash bonus Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:17 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 1,803 | $1.82 | $3,281.46 |
DisclosureSEC source: 0001437749-26-021444 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,038 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:14 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 1,593 | $2.06 | $3,281.58 |
DisclosureSEC source: 0001437749-26-019994 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,235 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:11 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantCommon Stock | 1,491 | $2.20 | $3,280.20 |
DisclosureSEC source: 0001437749-26-018545 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,642 F1 · shares: Stock granted in lieu of cash for portion of base salary Read SEC document |
| February 26, 2026 Filed May 20, 2026 22:03 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.70 Strike: $0.70 | $105,000.00 |
DisclosureSEC source: 0001104659-26-064653 · tm267728-3_4seq1.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2036-02-26 F1 · security: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F1 · price: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2 · derivative.exercise_date: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:05 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 56,187 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0001437749-26-000604 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,187 Underlying: Common Stock · 56,187 shares Expires 2036-01-02 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:14 UTC | Imunon, Inc. IMNN · Entity 8041 | Exercise / conversionRestricted Stock · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-028685 · rdgdoc.xml · derivative · entry 3 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock. F3 · derivative.exercise_date: On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date. F3 · derivative.expiration_date: On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date. Read SEC document |
| September 06, 2025 Filed Sep 9, 2025 20:14 UTC | Imunon, Inc. IMNN · Entity 8041 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-028685 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:21 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.20 | $0.00 |
DisclosureSEC source: 0001437749-25-025084 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2035-08-04 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:15 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001437749-25-008256 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-03-14 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:32 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000889 · tm251864-4_4seq1.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,229 F1 · shares: Represents shares of restricted stock units ("RSUs") awarded under the 2014 Stock Incentive Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. F2 · balance_after: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. Read SEC document |
| September 06, 2024 Filed Sep 10, 2024 20:49 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 63,602 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001437749-24-028877 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 302,768 Underlying: Common Stock · 63,602 shares Expires 2034-09-06 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F3 · shares: Option granted in lieu of cash payment increases. F2 · derivative.exercise_date: The options vest as follows 1/2 on the date of grant; 1/4 on the one year anniversary of the grant; and 1/4 on the second anniversary of the date of grant. Read SEC document |
| September 06, 2024 Filed Oct 31, 2024 23:57 UTC Amendment | Imunon, Inc. IMNN · Entity 8041 | GrantRestricted Stock Units · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-032858 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: This amendment reports a new transaction that was inadvertently omitted from the Form 4 filed on September 10, 2024 by the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of Imunon, Inc.'s common stock. F2 · derivative.exercise_date: On September 6, 2024, Ms. Lindborg received restricted stock units representing 25,000 shares subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date. F2 · derivative.expiration_date: On September 6, 2024, Ms. Lindborg received restricted stock units representing 25,000 shares subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date. Read SEC document |
| August 15, 2024 Filed Aug 16, 2024 12:03 UTC | Imunon, Inc. IMNN · Entity 8041 | PurchaseImunon Common Stock | 25,000 | $0.98 | $24,500.00 |
DisclosureSEC source: 0001437749-24-027060 · rdgdoc.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,166 F1 · shares: The CEO and president purchased the shares on the open market. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 10:13 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001437749-24-020264 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,166 Underlying: Common Stock · 112,500 shares Expires 2034-06-12 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows 1/4 on the one year anniversary of the grant and 1/4 on the second, third and fourth year anniversary Read SEC document |
| May 13, 2024 Filed May 14, 2024 20:24 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001437749-24-016643 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,666 Underlying: Common Stock · 112,500 shares Expires 2034-05-13 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant F2 · derivative.exercise_date: The options vest as follows 1/4 on the one year anniversary of the grant and 1/4 on the second, third and fourth year anniversary Read SEC document |
| March 15, 2024 Filed Mar 18, 2024 21:04 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001437749-24-008334 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,166 Underlying: Common Stock · 4,500 shares Expires 2034-03-15 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second anniversary of the date of grant. Read SEC document |
| March 11, 2024 Filed Mar 14, 2024 00:57 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 241,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-034095 · tm248822-4_4seq1.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 423,435 F1 · shares: The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 21:16 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 11,500 | $1.77 | $20,402.15 |
DisclosureSEC source: 0001104659-23-098326 · tm2325491-1_4seq1.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.74 to $1.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 02, 2023 Filed Aug 7, 2023 10:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-088000 · tm2322868-1_4seq1.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of August 2, 2023, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 10:42 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-048632 · tm2313513-1_4seq1.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,000 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares were fully vested upon grant. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:39 UTC | Imunon, Inc. IMNN · Entity 8041 | GrantStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001437749-23-007405 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,666 Underlying: Common Stock · 2,000 shares Expires 2033-03-17 F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the date of grant; 1/3 on the on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant. Read SEC document |
| December 07, 2022 Filed Jan 4, 2023 12:36 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-000636 · tm231419-1_4seq1.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · Co-Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · shares: Shares acquired are shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of December 7, 2022, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:47 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Common Stock · Derivative | 2,500 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001437749-22-015068 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,666 Underlying: Celsion Corporation Common Stock · 2,500 shares Expires 2032-06-13 F1 · derivative.exercise_price: Represents the per share fair value of the Common Stock based on the closing price of a share of Celsion Corporation Common Stock on the date of the grant. F2 · derivative.exercise_date: The Options vest as follows: 1/3 on the date of the grant, 1/3 on the one year anniversary of the date of the grant, and 1/3 on the second year anniversary of the date of the grant. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 23:01 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 2,500 | $0.00 Strike: $4.60 | $0.00 |
DisclosureSEC source: 0001437749-22-005432 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,166 Underlying: Celsion Corporation Common Stock · 2,500 shares Expires 2032-03-04 F1 · derivative.exercise_price: Represents the per share per share fair value of the common stock based on the closing price of a share of Celsion Stock on the date of the award. F2 · derivative.exercise_date: The options vest as follows: 1/3 on the date of grant; 1/3 on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:21 UTC | Imunon, Inc. CLSN · Entity 8041 | GrantOption to Purchase Celsion Corporation Common Stock · Derivative | 40,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001437749-21-014321 · rdgdoc.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Celsion Corporation Common Stock · 40,000 shares Expires 2031-06-04 F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant. F2 · derivative.exercise_date: The options vest as follows: 1/3 on January 1, 2022; 1/3 on January 1, 2023; and 1/3 on January 1, 2024. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 23:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCall Option (right to buy) · Derivative | 200 | $11,000.00 Strike: $10.00 | $2,200,000.00 |
DisclosureSEC source: 0001104659-20-127446 · tm2036490-1_4.xml · derivative · entry 1 Lindborg Stacy · CIK 0001813667 · EVP, Head Global Clin Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 Underlying: Common Stock · 20,000 shares Expires 2021-05-21 Read SEC document |
| June 01, 2020 Filed Jun 1, 2020 21:32 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $7.67 | $0.00 |
DisclosureSEC source: 0001104659-20-068501 · tm2021119-2_4.xml · derivative · entry 2 Lindborg Stacy · CIK 0001813667 · EVP, Head Global Clin Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-06-01 F2 · derivative.exercise_date: The option, awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan, shall vest and become exercisable as to 50,000 of the underlying shares on February 28, 2021 ("First Vesting Date"), and the remaining 50,000 shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter until fully vested and exercisable on the second anniversary of the First Vesting Date, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. Read SEC document |
| June 01, 2020 Filed Jun 1, 2020 21:32 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-068501 · tm2021119-2_4.xml · nonDerivative · entry 1 Lindborg Stacy · CIK 0001813667 · EVP, Head Global Clin Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Shares acquired are shares of restricted stock awarded on June 1, 2020 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 100% of the award on December 31, 2020, provided that the Reporting Person remains continuously employed by Issuer from the date of grant through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.